Published in J Biol Chem on April 12, 2002
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol (2004) 4.08
Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J (2004) 3.10
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J (2005) 2.29
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell (2009) 2.00
Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci U S A (2005) 1.97
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
MDMX regulation of p53 response to ribosomal stress. EMBO J (2006) 1.77
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J (2006) 1.67
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A (2011) 1.66
DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol (2005) 1.56
DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. Mol Cell Biol (2002) 1.53
Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol (2003) 1.51
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol (2003) 1.49
Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol (2005) 1.41
14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J (2006) 1.40
MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol (2007) 1.33
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem (2011) 1.27
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget (2012) 1.24
The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol (2010) 1.23
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One (2013) 1.22
A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med (2012) 1.18
A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther (2010) 1.13
Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol (2011) 1.12
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev (2010) 1.11
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle (2008) 1.11
Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev (2011) 1.11
Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle (2010) 1.09
Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J Biol Chem (2008) 1.06
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer (2012) 1.06
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol (2008) 1.01
MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res (2012) 1.00
Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. J Biol Chem (2010) 1.00
HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. J Biol Chem (2010) 1.00
A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia (2011) 1.00
Full-length hdmX transcripts decrease following genotoxic stress. Oncogene (2008) 0.99
E3 ligases determine ubiquitination site and conjugate type by enforcing specificity on E2 enzymes. J Biol Chem (2011) 0.97
Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2. Mol Cell Biol (2006) 0.96
Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo. Mol Cell Biol (2010) 0.95
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov (2011) 0.94
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene (2011) 0.90
Hydrophilic residues are crucial for ribosomal protein L11 (RPL11) interaction with zinc finger domain of MDM2 and p53 protein activation. J Biol Chem (2011) 0.89
MDMX exerts its oncogenic activity via suppression of retinoblastoma protein. Oncogene (2015) 0.88
c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation. J Biol Chem (2010) 0.87
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia. Oncotarget (2014) 0.87
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1. World J Biol Chem (2014) 0.84
Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2. Neoplasia (2011) 0.84
Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des (2013) 0.84
Predicted functions of MdmX in fine-tuning the response of p53 to DNA damage. PLoS Comput Biol (2010) 0.83
Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene (2012) 0.82
The Roles of MDM2 and MDMX Phosphorylation in Stress Signaling to p53. Genes Cancer (2012) 0.81
Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts. Mol Cancer (2011) 0.81
Stochastic modeling and simulation of the p53-MDM2/MDMX loop. J Comput Biol (2009) 0.81
Stochastic and Deterministic Models of Cellular p53 Regulation. Front Oncol (2013) 0.80
High levels of Hdmx promote cell growth in a subset of uveal melanomas. Am J Cancer Res (2012) 0.80
Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells. Cancer Biol Ther (2014) 0.80
The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance. Mol Biol Cell (2007) 0.80
Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo. Cell Cycle (2009) 0.79
A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53. J Biol Chem (2010) 0.79
A protein turnover signaling motif controls the stimulus-sensitivity of stress response pathways. PLoS Comput Biol (2013) 0.79
p53 binds the mdmx mRNA and controls its translation. Oncogene (2016) 0.78
Deconstructing nucleotide binding activity of the Mdm2 RING domain. Nucleic Acids Res (2010) 0.78
Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biol Ther (2007) 0.77
Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis (2015) 0.77
Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection. Cell Cycle (2012) 0.77
Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene (2016) 0.77
Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget (2016) 0.77
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. Oncoscience (2014) 0.76
The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells. Oncogenesis (2016) 0.76
Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions. Mol Cell Biol (2016) 0.76
An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC Clin Pathol (2013) 0.76
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl Cancer Res (2016) 0.76
Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis. Dev Biol (2014) 0.75
Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB. Genes Cancer (2016) 0.75
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy. Mol Ther Oncolytics (2017) 0.75
Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria. Oncotarget (2016) 0.75
Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol (2008) 3.22
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
MDM2, an introduction. Mol Cancer Res (2003) 2.87
MDMX: from bench to bedside. J Cell Sci (2007) 2.78
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat (2009) 2.76
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res (2007) 2.35
Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell (2009) 2.28
A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol Cell (2005) 2.15
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem (2003) 2.03
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci U S A (2005) 1.97
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem (2003) 1.93
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res (2006) 1.93
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun (2005) 1.85
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol (2005) 1.79
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res (2007) 1.70
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet (2003) 1.68
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A (2011) 1.66
Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination. Mol Cell Biol (2005) 1.65
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest (2007) 1.64
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol (2007) 1.58
DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol (2005) 1.56
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res (2008) 1.54
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest (2011) 1.54
Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol (2003) 1.51
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol (2003) 1.49
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res (2006) 1.47
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
Mdmx and Mdm2: brothers in arms? Cell Cycle (2004) 1.44
p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A (2006) 1.41
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One (2009) 1.39
RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis (2003) 1.37
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol (2006) 1.35
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Similar effects of Brca2 truncation and Rad51 paralog deficiency on immunoglobulin V gene diversification in DT40 cells support an early role for Rad51 paralogs in homologous recombination. Mol Cell Biol (2005) 1.33
p53: a guide to apoptosis. Curr Cancer Drug Targets (2008) 1.33
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res (2003) 1.32
The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity (2010) 1.31
Histone chaperone activity of Fanconi anemia proteins, FANCD2 and FANCI, is required for DNA crosslink repair. EMBO J (2012) 1.30
c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res (2003) 1.30
c-Abl interacts with the WAVE2 signaling complex to induce membrane ruffling and cell spreading. J Biol Chem (2006) 1.29
ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle (2005) 1.29
Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res (2005) 1.28
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 1.27
Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem (2005) 1.23
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res (2010) 1.23
Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol (2006) 1.22
Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene (2005) 1.22
Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene (2005) 1.21
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest (2011) 1.21
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation (2007) 1.21
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell (2010) 1.21
A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi. Genomics Proteomics Bioinformatics (2010) 1.20
EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res (2008) 1.17
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol (2007) 1.17
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol (2010) 1.15
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 1.15
Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis (2002) 1.14
Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol (2011) 1.12
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res (2010) 1.12
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev (2013) 1.11
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res (2012) 1.09
Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene (2002) 1.09